

**Supplementary Table 1.** Baseline characteristics, significant psychiatric symptoms and mental disorders 4 months after discharge in patients treated by three drug treatment and matched controls

	HCQ (n = 18)	Controls <sup>a</sup> (n = 72)	Anti-IL-6 (n = 27)	Controls <sup>b</sup> (n = 108)	CTC (n = 7)	Controls <sup>c</sup> (n = 28)
Baseline characteristics						
Age (yr)	57.55 ± 11.5	57.50 ± 13.00	61.6 ± 10.5	60.1 ± 13.2	52.7 ± 8.5	55.9 ± 11.3
Female	4 (22.2)	17 (23.6)	9 (33.3)	36 (33.3)	1 (14.3)	7 (25.0)
BMI (kg/m <sup>2</sup> )	29.7 ± 5.4	28.4 ± 7.0	27.56 ± 7.4	28.7 ± 7.7	29.6 ± 6.8	29.2 ± 4.2
History of psychiatric disorders	1 (5.6)	4 (5.6)	6 (22.2)	11 (10.2)	1 (14.3)	3 (10.7)
High blood pressure	7 (38.9)	29 (40.3)	15 (55.6)	53 (49.1)	1 (14.3)	11 (39.3)
Type 2 diabete	5 (27.8)	24 (33.3)	7 (25.9)	40 (37.0)	2 (28.6)	10 (35.7)
COPD	0	2 (2.8)	0	4 (3.7)	0	1 (3.6)
Asthma	5 (27.8)	9 (12.5)	3 (11.1)	15 (13.9)	0	4 (14.3)
Smoking	1 (5.6)	1 (5.6)	5 (18.5)	6 (5.6)	0	4 (14.3)
Antidepressant drugs	1 (5.6)	2 (2.8)	4 (14.8)	6 (5.6)	0	1 (3.6)
CRP	113.9 ± 87.4*	193.6 ± 110.8	170.4 ± 102.7	162.7 ± 116.6	284.7 ± 157.4	237.0 ± 126.0
Maximal creatininemia	160.1 ± 178.3	107.2 ± 76.9	179.2 ± 219.0	134.3 ± 170.9	124.9 ± 114.2	131.6 ± 112.9
Intubation	7 (38.9)	32 (44.4)	12 (44.4)	39 (36.1)	5 (71.4)	18 (64.3)
ICU stay	13 (72.2)	53 (73.6)	20 (74.1)	76 (70.4)	7 (100.0)	28 (100.0)
Significant psychiatric symptoms 4 months after the acute COVID-19 infection						
Insomnia (ISI > 14)	4 (22.2)	10 (14.5)	6 (22.2)	18 (17.5)	0	4 (14.3)
Anxiety (HAD > 7)	9 (50.0)*	15 (21.7)	10 (37.0)	23 (21.3)	1 (14.3)	9 (32.1)
Depression (BDI > 7)	4 (22.2)	11 (15.7)	9 (33.3)*	15 (13.9)	0	4 (14.3)
Mental disorders 4 months after the acute COVID-19 infection						
All mental disorders	6 (33.3)	12 (16.7)	8 (29.6)	14 (13.0)	1 (14.3)	5 (17.9)
Major depressive disorders	5 (27.8)	10 (13.9)	6 (22.2)	10 (9.3)	1 (14.3)	2 (7.1)
Anxiety disorders	2 (11.1)	9 (12.5)	4 (14.8)	5 (4.6)	0	2 (7.1)

Values are presented as mean ± standard deviation or number (%).

HCQ, hydroxychloroquine; Anti-IL-6, interleukin-6 receptor antagonists; CTC, corticotherapy; BMI, body mass index COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ICU, intensive care unit; ISI, Insomnia Severity Index; HAD, Hospital Anxiety and Depression; BDI, Beck Depression Inventory.

<sup>a</sup>Propensity-matched cohort on age, sex, history of psychiatric disorders and ICU stay with a 4:1 matching. <sup>b</sup>Propensity-matched cohort on age, sex, history of psychiatric disorders, ICU stay, antidepressant drugs, maximal creatininemia and Intubation with a 4:1 matching. <sup>c</sup>Propensity-matched cohort on age, sex, history of psychiatric disorders, CRP, ICU stay and intubation with a 4:1 matching.

\*Statistically significant in comparison to controls ( $p < 0.05$ ).